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Background: Patients with antibody deficiencies depend on the presence of a variety of antibody specificities in
intravenous immunoglobulin (IVIG) to ensure continued protection against pathogens. Few studies have examined
levels of antibodies to specific pathogens in IVIG preparations and little is known about the specific antibody levels in
patients under regular IVIG treatment. The current study determined the range of antibodies to tetanus, diphtheria,
measles and varicella in IVIG products and the levels of these antibodies in patients undergoing IVIG treatment.
Methods: We selected 21 patients with primary antibody deficiencies who were receiving regular therapy with IVIG.
Over a period of one year, we collected four blood samples from each patient (every 3 months), immediately before
immunoglobulin infusion. We also collected samples from the IVIG preparation the patients received the month prior
to blood collection. Antibody levels to tetanus, diphtheria, measles and varicella virus were measured in plasma and
IVIG samples. Total IgG levels were determined in plasma samples.
Results: Antibody levels to tetanus, diphtheria, varicella virus and measles showed considerable variation in different
IVIG lots, but they were similar when compared between commercial preparations. All patients presented with
protective levels of antibodies specific for tetanus, measles and varicella. Some patients had suboptimal diphtheria
antibody levels. There was a significant correlation between serum and IVIG antibodies to all pathogens, except
tetanus. There was a significant correlation between diphtheria and varicella antibodies with total IgG levels, but there
was no significant correlation with antibodies to tetanus or measles.
Conclusions: The study confirmed the variation in specific antibody levels between batches of the same brand of IVIG.
Apart from the most common infections to which these patients are susceptible, health care providers must be aware
of other vaccine preventable diseases, which still exist globally.
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Intravenous immunoglobulin (IVIG) is a therapeutic prep-
aration containing pooled antibodies (IgG) from blood and
plasma donors. One of the main areas of IVIG application
is as antibody replacement therapy in patients with quan-
titative or qualitative antibody deficiencies. These patients
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unless otherwise stated.specificities in IVIG to ensure continued protection
against any viral or microbial pathogens they might en-
counter. The broad spectrum of antimicrobial activities in
these preparations is crucial for reducing infections [1,2].
Many factors may have an impact on the quality and
quantity of antibodies in immunoglobulin products [2,3].
Differences in some specific titres between commercially
available products have been shown [3-5]. Moreover,
nowadays, for some diseases, plasma donor immunity is
conferred by vaccination and not by natural infectionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Pathogen-specific antibody levels in IVIG
preparations
IVIG Mean IU/mL SD Number of lots
Tetanus 19,92 10,19 38
Immunoglobulin® 20,04 1,60 2
Endobulin® 9,25 1,45 3
Flebogamma® 26,02 10,64 6
Octagam® 18,99 7,91 16
Tegeline® 18,64 13,68 9
Vigam® 30,58 3,70 2
Diphtheria 10,97 9,58 38
Immunoglobulin® 12,87 6,97 2
Endobulin® 7,82 5,29 3
Flebogamma® 19,86 19,35 6
Octagam® 10,05 6,48 16
Tegeline® 7,75 4,11 9
Vigam® 8,98 5,41 2
Measles 28,53 18,53 38
Immunoglobulin® 43,15 41,56 2
Endobulin® 9,65 0,53 3
Flebogamma® 35,04 12,73 6
Octagam® 23,04 16,10 16
Tegeline® 39,06 18,76 9
Vigam® 19,04 6,98 2
Varicella 21,75 12,19 38
Immunoglobulin® 19,47 10,87 2
Endobulin® 11,06 7,88 3
Flebogamma® 32,26 11,30 6
Octagam® 21,60 13,28 16
Tegeline® 20,90 10,12 9
Vigam® 13,62 0,42 2
The bold data represent the mean for all of the 38 different lots.
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vaccine-induced immunity and a decrease in specific
antibody levels to some diseases [6-8].
Despite the importance of IVIG in conferring protec-
tion, few studies have examined levels of antibodies to
specific pathogens in IVIG preparations and little is
known about the specific antibody levels in patients with
antibody deficiency under regular IVIG treatment. In re-
placement therapy it is important that patients receive
protective levels of antibodies to infections that are pre-
ventable by vaccines and, also, to common pathogens that
cause infections in patients with antibody deficiencies.
The objective of the current study was to determine the
range of antibodies to some bacterial and viral pathogens in
IVIG products and also the levels of these antibodies in pa-
tients undergoing IVIG treatment, over a one-year period.
Results
We selected 21 patients with a mean age of 25 years old, 11
male, with the following diagnosis: six with X-linked
Agammaglobulinemia (XLA), twelve with Common Vari-
able Immunodeficiency (CVID) and three with Hyper IgM
Syndrome (HIM), who were undergoing regular IVIG re-
placement therapy every 4 weeks. The hallmark of these
immunodeficiency diseases is a severely impaired IgG pro-
duction. The mean IgG at diagnosis was 226 mg/dL (range
5–564,6 mg/dL; normal values in adults: 739–1390 mg/dL).
The mean IgG level during the study was 778 mg/dL (range
459–1220 mg/dL) and the mean IVIG dose was 553 mg/
kg/month (range 340–760 mg/kg/month). Over the study,
the IVIG dose remained unchanged for each patient.
Most patients received more than one IVIG commercial
preparation during the study, because they depend on the
preparation provided by the government.
Thirty-eight lots of six different commercial IVIG prep-
arations and eighty-four plasma samples were evaluated.
Antibody levels in IVIG preparations
Antibody levels to tetanus, diphtheria, varicella and measles
showed considerable variation in each of the 38 different
lots (Table 1). For all antigens tested, the coefficient of
variation was greater than 50% (Table 1).
The titres of antibodies were compared between com-
mercial preparations of Flebogamma®, Octagam® and
Tegeline®. Titres to tetanus, diphtheria, varicella and
measles were similar for these three products (tetanus:
p = 0.051; diphtheria: p = 0.254; varicella: p = 0.615; mea-
sles: p = 0.588). Immunoglobulin®, Endobulin® and Vigam®
were administered only to a few patients so we did not
have sufficient numbers of lots for comparison (Table 1).
IgG and antibody levels in serum samples
IgG and antibody levels did not remain constant during
the follow up. There was considerable variation in specificantibody and total IgG levels throughout the year in these
patients (Table 2).
All patients presented protective levels of tetanus, measles
and varicella antibodies. There were patients with subopti-
mal diphtheria antibody levels (Table 2 - minimum values).
Correlation of serum specific antibodies with IVIG
specific antibodies
There was significant correlation between serum and IVIG
antibodies to all pathogens, except tetanus (Figure 1).
Correlation of pathogen-specific antibodies with total
IgG levels
There was a significant correlation between diphtheria
and varicella antibodies with total IgG levels, but there
Table 2 IgG and antibody levels in serum samples for
each of the four samplings
Mean SD Min Max n
Tetanus (IU/mL)
First sample 0,82(A) 0,28 0,34 1,57 21
Second sample 1,72(B) 0,77 0,79 3,48 21
Third sample 1,82(B) 0,81 0,16 3,25 21
Fourth sample 2,22(B) 2,22 0,17 9,90 21
Diphtheria (IU/mL)
First sample 0,49(C) 0,25 0,07 0,96 21
Second sample 0,61(C) 0,38 0,14 1,53 21
Third sample 0,64(C) 0,46 0,08 1,65 21
Fourth sample 1,22(D) 0,53 0,16 2,15 21
Measles (IU/mL)
First sample 2,21(E) 0,67 0,81 3,47 21
Second sample 2,88(E) 1,83 0,86 6,82 21
Third sample 1,74(F) 0,99 0,60 4,30 21
Fourth sample 2,66(E) 1,51 1,09 7,94 21
Varicella (IU/mL)
First sample 0,86(G) 0,84 0,27 4,06 21
Second sample 1,45(H) 0,60 0,70 2,57 21
Third sample 1,50(H) 0,61 0,48 2,67 21
Fourth sample 2,33(I) 1,18 0,60 5,27 21
Total IgG (mg/dL) – plasma
samples
First sample 748,71(J) 167,26 459,0 1040,0 21
Second sample 741,76(J) 154,01 521,0 1030,0 21
Third sample 754,19(J) 162,62 535,0 1070,0 21
Fourth sample 868,62(K) 162,85 634,0 1220,0 21
(A)and (B)have different mean at a significant level of 5% (p = 0.017).
(C)and (D)have different mean at a significant level of 5% (p < 0.001).
(E)and (F)have different mean at a significant level of 5% (p = 0.043).
(G),(H) and (I)have different mean at a significant level of 5% (p < 0.001).
(J)and (K)have different mean at a significant level of 5% (p = 0.0156).
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(Figure 2).
Antibody levels to tetanus, diphtheria, varicella and
measles were similar between patients with XLA and pa-
tients with CVID and HIM. (tetanus: p = 0.680; diphtheria:
p = 0.221; varicella: p = 0.73; measles: p = 0.360).
Antibody levels to tetanus, varicella and measles were
similar between patients receiving IVIG doses equal or
greater than 500 mg/kg and patients receiving doses smaller
than 500 mg/kg (tetanus: p = 0.665; varicella: p = 0.140;
measles: p = 0.592). Antibody levels to diphtheria were
greater in patients receiving IVIG doses greater than 500
mg/kg (p = 0.031).
Discussion
Recent studies have shown that for some microorganisms
there is significant variation in antibody levels in IVIGpreparations of different brands, as well as in different
batches of the same brand [5-7]. For measles, varicella, tet-
anus and diphtheria, there was no significant difference in
antibody concentrations between the three different com-
mercial preparations of IVIG. However, there is variability
in the levels of these antibodies among different batches
of the same brand, which probably correlates to plasma
donor’s antibody levels.
Several studies have shown the efficacy of IVIG treat-
ment in reducing the number and severity of infections
in patients with humoral deficiency [9-13]. Most studies,
however, focus their attention on the ability of the treat-
ment to reduce the number of respiratory infections,
since this is the main cause of death in this population
[9-13]. Little is discussed in relation to protection
against less common but potentially serious infectious
diseases. During this study, one patient with diagnosis of
XLA, in regular use of IVIG, developed mild varicella
zoster infection, despite adequate levels of specific anti-
bodies against varicella (2,03 IU/mL) on first day of in-
fection. Serum levels of specific antibodies against
various pathogens have been associated with protection.
Some studies have shown that individuals with specific
serum antibody levels do not develop disease after ex-
posure to some pathogen [14]. However, these protective
levels are usually determined after active immunization
in people who can produce antibodies. There are no
known studies that outline what the minimum serum
antibody levels against measles, varicella, tetanus or
diphtheria should be that can ensure protection by pas-
sive immunization for patients who do not produce their
own antibodies.
We expected that all patients regularly using adequate
doses of IVIG would have protective antibody levels
against these diseases. However, two patients had diph-
theria antibody concentrations below the recommended
protective levels. Although it was only observed on one
occasion, these patients susceptibility to diphtheria was
worrying, as this disease has not yet been eradicated
here in Brazil. The diphtheria antibody concentration in
the patients’s serum may be associated, among other fac-
tors, with the levels of these antibodies in IVIG prepara-
tions used, as we observed a significant positive linear
correlation between the specific serum antibody concen-
tration from each patient and the samples of adminis-
tered IVIG to these patients the previous month.
Antibody levels for vaccine preventable disease, such as
measles, have been reduced in IVIG in recent years due
to the increased number of vaccinated donors and the
reduction of wild-type pathogen circulating [6].
The effective dosing of IVIG in patients with antibody
deficiencies is determined by their ability to control in-
fections and the residual total IgG level (collected imme-
diately prior to IVIG infusion) [1,2]. In these patients,
Figure 1 Correlation between serum and IVIG antibodies. Measles: r = 0.232; p = 0.034. Varicella: r = 0.342; p = 0.001. Tetanus: r = 0.189;
p = 0.084. Diphtheria: r = 0.355; p = 0.001.
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measured. There is no consensus on the ideal dose to be
administered or the ideal total IgG level maintained by
the patient on regular use of IVIG. Nowadays it is highly
recommended that the IVIG dose, as well as the serum
total IgG target should be analyzed individually [10,15-17].Figure 2 Correlation between pathogen-specific antibodies with tota
p = 0.005. Tetanus: r = 0.209; p = 0.057. Diphtheria: r = 0.377; p = 0.0004.However, some patients with satisfactory total IgG levels
develop infections against pathogens which they should be
theoretically protected against by IVIG. Recent studies have
hypothesized that even while maintaining an adequate level
of total IgG, some patients may not have sufficient levels of
specific antibodies to various pathogens [10,17]. Forl IgG levels. Measles: r = 0.210; p = 0.056. Varicella: r = 0.302;
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relation between total IgG serum concentration and spe-
cific antibodies, however, one patient with diphtheria
antibody levels below the recommended protective level,
had a total IgG concentration greater than 1g/dL. For mea-
sles and tetanus, there was no significant correlation be-
tween the total IgG serum concentration and specific
antibody concentrations in the patients. We suggest that a
satisfactory level of total IgG does not necessarily mean ad-
equate levels of specific antibodies in the same individual,
for some pathogens.
Conclusions
Our study assumed that the heterogeneity of the im-
mune status of the potential plasma donor from the
healthy population may have implications on specific
antibody levels in immunoglobulin preparations and our
study also strengthened the variation in specific antibody
concentrations between batches of the same brand of
IVIG. Apart from the most common infections to which
these patients are susceptible, health care providers must
be aware of other vaccine preventable diseases, which
still exist globally.
Methods
We conducted this trial at the Federal University of São
Paulo - Brazil. The study protocol was approved by the
Ethics Committee at the University and a written in-
formed consent was obtained from each enrolled patient
or from his/her parents.
We selected 21 patients with primary antibody defi-
ciencies: X-linked Agammaglobulinemia (XLA), Com-
mon Variable Immunodeficiency (CVID) and Hyper IgM
syndrome (HIM), who were under regular replacement
therapy with IVIG (every 4 weeks) for a minimum of
two years. Patients with protein loss disorders were ex-
cluded from the study. Over a period of one year, from
2009 to 2010, we collected 4 blood samples from each of
these patients (every 3 months), immediately before im-
munoglobulin infusion. We also collected samples from
the IVIG that these patients had received the month prior
to blood collection. Antibody levels to tetanus, diphtheria,
measles and varicella were determined in plasma and
IVIG samples. Total IgG levels were determined only in
plasma samples.
Diphtheria and tetanus IgG antibodies were measured
by an in-house double-antigen ELISA and measles and
varicella IgG antibodies were measured by an in-house
indirect ELISA:
 Double antigen ELISA to detect tetanus antibodies:
Tetanus toxoid (Butantan Institute) diluted in 0.1M
carbonate-bicarbonate buffer, pH 9.6, was used to
coat 96-well microtiter plates overnight at 4°C.Two-fold serial dilutions of plasma samples and of
tetanus reference serum (in-house standard cali-
brated against “Tetanus antitoxin human immuno-
globulin NIBSC reagent 1976 (76/589)”) in dilution
buffer (10 mM PBS, pH 7.2, 1% Triton X-100) with
1% bovine serum albumin were added to the plate
and incubated for 1 h at 37°C. Biotin-labeled tetanus
toxoid in dilution buffer was then added to the plate
and incubated for 1 h at 37°C. Streptavidin-alkaline
phosphatase conjugate (Zymed, San Francisco, CA,
USA) in dilution buffer was incubated for 1 h at 37°C.
p-Nitrophenyl-phosphate (Sigma, St. Louis, MO,
USA) in 1M diethanolamine, 5 mM magnesium
chloride buffer, pH 9.8, was used as substrate and
absorbance at 450 nm was read with an immunorea-
der ELX-800 (Bio-Tek Instruments, Winooski, VT,
USA). Between steps, the plate was washed five times
in dilution buffer. Tetanus antibodies are reported
as IU/mL using the curve comparison method to
transform optical density to concentration units.
 Double antigen ELISA to detect diphtheria
antibodies [18]. The same method was used for
diphtheria antibodies, with some modifications:
diphtheria toxoid (Butantan Institute), diphtheria
reference serum (in-house standard calibrated
against “Diphtheria antitoxin human serum 91/534” -
NIBSC reagent) and biotin-labeled diphtheria toxoid
were used. Diphtheria antibodies are reported as IU/
mL using the curve comparison method to transform
optical density to concentration units.
 Indirect ELISA to detect VZV antibodies [19].
Varicella IgG antibodies were assessed by an “in house”
indirect ELISA. MaxiSorp 96-well microtiter plates
(Nunc, New York, EUA) were coated with varicella
vaccine (Varilrix, SmithKline Beecham, Belgium) di-
luted 1:100 in 0.1M carbonate-bicarbonate buffer, pH
9.6, and incubated overnight at 4°C. Two-fold serial
dilutions of plasma samples and of varicella reference
serum [in house standard calibrated against “Varicella
zoster virus antibody human immunoglobulin-NIBSC
reagent (90/690)”] in 0.01M phosphate buffered saline
(PBS), pH 7.2 and 0.05% Tween 20 with 1% bovine
serum albumin (BSA) were added to the plate and in-
cubated for 1 h at 37°C. Reference serum was added
to 10 wells and serum samples were added to 3 wells,
in all twofold dilutions starting at 1:100. In the next
step, alkaline phosphatase conjugated rabbit anti-
human IgG, specific for γ-chains (Invitrogen, USA) di-
luted 1:500 in 0.01M PBS, pH 7.2 and 0.05% Tween
20, was incubated for 1 h at 37°C. pnitrophenyl-
phosphate disodium (Sigma, USA) in 0.1M diethano-
lamine, 0.005M magnesium chloride buffer, pH 9.8,
was used as substrate in a concentration of 1 mg/mL.
OD was read at 405 nm in an immunoreader ELX-
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struments, USA). Between steps, the plate was washed
five times in 0.01M PBS, pH 7.2 and 0.05% Tween 20.
All solutions were added in a 100 μL volume to mi-
croplate wells. Varicella zoster antibodies were
expressed in IU/mL using the curve comparison
method to transform optical density in concentration
units. In all plates two blank wells we always present,
and mean values were subtracted from all other wells.
 Indirect ELISA to detect measles antibodies: Measles
IgG antibodies were assessed by an “in house”
indirect ELISA. MaxiSorp 96-well microtiter plates
(Nunc, New York, EUA) were coated with measles
antigen (cell supernatant of measles-infected cells)
(Microbix, Toronto, Canada) or control measles
antigen (cell supernatant of non-infected cells)
(Microbix) diluted 1:100 in 0.1M carbonate-
bicarbonate buffer, pH 9.6, and incubated overnight
at 4°C. Two-fold serial dilutions of plasma samples
and of measles reference serum [in house standard
calibrated against the WHO International Standard
Anti-Measles Serum (NIBSC code: 66/202) in 0.01M
phosphate buffered saline (PBS), pH 7.2 and 0.05%
Tween 20 with 1% bovine serum albumin (BSA)
were added to the plate and incubated for 1 h at
37°C. Reference serum was added to 10 wells and
plasma samples were added to 3 wells, in all twofold
dilutions starting at 1:100. In the next step, alkaline
phosphatase conjugated rabbit anti-human IgG, spe-
cific for γ-chains (Invitrogen, USA) diluted 1:500 in
0.01M PBS, pH 7.2 and 0.05% Tween 20, was incu-
bated for 1 h at 37°C. p-Nitrophenyl-phosphate dis-
odium (Sigma, USA) in 0.1M diethanolamine,
0.005M magnesium chloride buffer, pH 9.8, was
used as substrate in a concentration of 1 mg/mL.
OD was read at 405 nm in an immunoreader ELX-
800, using 630 nm as a reference filter (Bio-Tek In-
struments, USA). Between steps, the plate was
washed five times in 0.01M PBS, pH 7.2 and 0.05%
Tween 20. All solutions were added in a 100 μL vol-
ume to microplate wells. Measles antibodies were
expressed in IU/mL using the curve comparison
method to transform optical density in concentration
units. OD values from wells coated with control anti-
gen were subtracted from OD values from wells
coated with measles antigen.
According to the levels established for the healthy
population, tetanus and diphtheria antibody levels equal
to or greater than 0.1 IU/mL were considered to be fully
protective, antibody levels equal to or greater than 0.01
and below 0.1 IU/mL were considered with basic immun-
ity and antibody levels below 0.01 IU/mL were considered
nonimmune [19]. Measles antibody levels equal to orgreater than 0.12 IU/mL were considered protective [20].
Varicella antibody levels equal to or greater than 0.1 IU/
mL were considered to be fully protective, antibody levels
equal to or greater than 0.05 and below 0.1 IU/mL were
considered with basic immunity and antibody levels below
0.05 IU/mL were considered nonimmune [21].
Statistical analysis
Mean, corresponding SDs, median, maximum and mini-
mum and CV were used to summarize values. The fol-
lowing tests were used to analyse the IVIG and plasma
antibody content: student’s t test, ANOVA and Kruskal-
Wallis. Correlation was analysed assuming Gaussian dis-
tribution (Pearson correlation). A P value of < 0.05 was
considered significant.
Abbreviations
ANOVA: Analysis of variance; CV: Coefficient of variation; ELISA: Enzyme-
linked immunosorbent assay; IVIG: Intravenous immunoglobulin;
SD: Standard deviation.
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